Literature DB >> 17722014

Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics.

Adriana Rocha1, Maria P Marques, Eduardo B Coelho, Vera L Lanchote.   

Abstract

Citalopram (CITA) is available as a racemic mixture and as a pure enantiomer. Its antidepressive action is related to the (+)-(S)-CITA and to the metabolite (+)-(S)-demethylcitalopram (DCITA). In the present investigation, a method for the analysis of CITA and DCITA enantiomers in human and rat plasma was developed and applied to the study of pharmacokinetics. Plasma samples (1 ml) were extracted at pH 9.0 with toluene:isoamyl alcohol (9:1, v/v). The CITA and DCITA enantiomers were analyzed by LC-MS/MS on a Chiralcel OD-R column. Recovery was higher than 70% for both enantiomers. The quantification limit was 0.1 ng/ml, and linearity was observed up to 500 ng/ml plasma for each CITA and DCITA enantiomer. The method was applied to the study of the kinetic disposition of CITA administered in a single oral dose of 20 mg to a healthy volunteer and in a single dose of 20 mg/kg (by gavage) to Wistar rats (n = 6 for each time). The results showed a higher proportion of the (-)-(R)-CITA in human and rat plasma, with S/R AUC ratios for CITA of 0.28 and 0.44, respectively. S/R AUC ratios of DCITA were 0.48 for rats and 1.04 for the healthy volunteer. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722014     DOI: 10.1002/chir.20452

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  7 in total

1.  Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.

Authors:  Adriana Rocha; Eduardo B Coelho; Stefânia A Sampaio; Vera L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats.

Authors:  Nieves Velez de Mendizabal; Kimberley Jackson; Brian Eastwood; Steven Swanson; David M Bender; Stephen Lowe; Robert R Bies
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-22       Impact factor: 2.745

Review 3.  PharmGKB summary: citalopram pharmacokinetics pathway.

Authors:  Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

4.  Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.

Authors:  Zheng Ye; Charlotte L Rae; Cristina Nombela; Timothy Ham; Timothy Rittman; Peter Simon Jones; Patricia Vázquez Rodríguez; Ian Coyle-Gilchrist; Ralf Regenthal; Ellemarije Altena; Charlotte R Housden; Helen Maxwell; Barbara J Sahakian; Roger A Barker; Trevor W Robbins; James B Rowe
Journal:  Hum Brain Mapp       Date:  2016-01-12       Impact factor: 5.038

5.  A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.

Authors:  Ayman Akil; Robert R Bies; Bruce G Pollock; Dimitrios Avramopoulos; D P Devanand; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Daniel Weintraub; Jerome Yesavage; David M Shade; Constantine G Lyketsos
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-26       Impact factor: 2.745

6.  Enantioseparation of Citalopram by RP-HPLC, Using Sulfobutyl Ether-β-Cyclodextrin as a Chiral Mobile Phase Additive.

Authors:  Yangfeng Peng; Quan Sophia He; Jiang Cai
Journal:  Int J Anal Chem       Date:  2016-01-05       Impact factor: 1.885

Review 7.  Chiral Drug Analysis in Forensic Chemistry: An Overview.

Authors:  Cláudia Ribeiro; Cristiana Santos; Valter Gonçalves; Ana Ramos; Carlos Afonso; Maria Elizabeth Tiritan
Journal:  Molecules       Date:  2018-01-28       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.